Request Trial
shutterstock_1191925942_canna_obscura
Canna Obscura / Shutterstock.com
11 August 2022Staff writer

Hemp group in cybersquatting clash

Illinois-based firm accuses hemp group of cybersquatting | US Court for the District of Colorado.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
WATCH: Interview with Mythili Markowski, director at Regeneron
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.
Europe
IP in the deal room: The risks that bite before, during and after closing
7 May 2026   Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.
Americas
Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’
7 May 2026   A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.


Editor's picks

From the courtroom: Hikma v Amarin SCOTUS oral arguments
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026

Editor's picks

Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026

More features

WATCH: Interview with Mythili Markowski, director at Regeneron
IP in the deal room: The risks that bite before, during and after closing
Teva can pursue monopoly claims over rival’s ‘exclusive pharmacy deal’
Five generations at work: How teams are bridging the gap
Kilpatrick adds tech patent litigator and China expert to Chicago office
US judge allows rare patent defence in ‘world’s smallest heart pump’ suit
WATCH: John Ward, trademarks VP and associate GC of Moderna, at INTA
WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular